Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 00:00:00 01/08/2026 +04			5-day change	1st Jan Change
130.21 ^USD	-0.82%		+0.70%	+6.09%

07-30	Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials	RE
07-28	Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial	MT

Transcript : Gilead Sciences, Inc. - Special Call

Published on 04/08/2026 at 03:00 am +04 - Modified on 04/08/2026 at 07:50 am +04

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good afternoon. Thank you for attending today's Gilead Sciences update on proposed Tubulis, Ouro and Arcellx acquisitions call. My name is Tamia, and I

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

Latest news about Gilead Sciences, Inc.

07-30	Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials	RE
07-28	Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial	MT
07-28	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT
07-24	Gilead Sciences, Inc. Recommends Trodelvy Plus Keytruda In PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer	CI
07-24	Gilead Sciences Says EMA Recommends Trodelvy-Keytruda Combination for Breast Cancer	MT
07-24	Merck licenses experimental HIV pill to generic makers in 129 countries	RE
07-23	Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating	MT
07-22	What Bundibugyo Ebola vaccines and treatments are under development	RE
07-21	Gilead Sciences Shares Fall After Downgrade From Leerink Partners	MT
07-21	Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials	RE
07-21	Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike…
07-21	Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146	MT
07-16	Kalshi to allow bets on clinical trials, FDA decisions	RE
07-15	African markets - factors to watch on July 15	RE
07-14	Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo	RE